Availability, price and affordability of anti-tuberculosis drugs in Europe: A TBNET survey

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 1081-1088

  Günther, Gunar ^a,b   Gomez, Gabriela B ^c,d   Lange, Christoph ^a,b   Rupert, Stephan ^c   Van Leth, Frank ^c  

^a German Center for Infection Research   (Germany)

^b UNIVERSITY OF NAMIBIA   (Namibia)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE PLUS TERIZIDON; ETHAMBUTOL; ETHIONAMIDE PLUS PROTHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG COST; DRUG RESISTANT TUBERCULOSIS; EUROPE; GROSS NATIONAL PRODUCT; HEALTH CARE AVAILABILITY; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PURCHASING; CLINICAL TRIAL; COMPARATIVE STUDY; ECONOMICS; EUROPEAN UNION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; MALE; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; DRUG COSTS; EUROPEAN UNION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84926429946     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00124614     Document Type: Article

References (21)

1. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
2. Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 2014; 43: 1763-1775.
3. Winston CA, Navin TR, Becerra JE, et al. Unexpected decline in tuberculosis cases coincident with economic recession - United States, 2009. BMC Public Health 2011; 11: 846.
4. Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4: e238.
5. Arinaminpathy N, Dye C. Health in financial crises: economic recession and tuberculosis in Central and Eastern Europe. J R Soc Interface 2010; 7: 1559-1569.
6. Karanikolos M, Mladovsky P, Cylus J, et al. Financial crisis, austerity, and health in Europe. Lancet 2013; 381: 1323-1331.
7. Giehl C, Lange C, Duarte R, et al. TBNET - Collaborative research on tuberculosis in Europe. Eur J Microbiol Immunol 2012; 2: 264-274.
8. th ed. Geneva, World Health Organization, 2010.
9. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva, World Health Organization, 2011.
10. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
11. World Bank. PPP. conversion factor, GDP (LCU per international $). http://data.worldbank.org/indicator/PA.NUS.PPP Date last accessed: April 19 2014.
12. World Bank. GDP. per capita, PPP (current international $). http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD Date last accessed: April 19 2014.
13. Sotgiu G, D'Ambrosio L, Centis R, et al. Availability of anti-tuberculosis drugs in Europe. Eur Respir J 2012; 40: 500-503.
14. Van derWerf M, Kodmon C, Hollo V, et al. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012. Euro Surveill 2014:19; pii=20733.
15. Hoen E't, Berger J, Calmy A, et al. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc 2011; 14: 15.
16. Arinaminpathy N, Cordier-Lassalle T, Vijay A, et al. The Global Drug Facility and its role in the market for tuberculosis drugs. Lancet 2013; 382: 1373-1379.
17. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 Patients. PLoS Med 2012; 9: e1001300.
18. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
19. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
20. Shi L, Hodges M, Drummond M, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report-Part VI. Value Health 2010; 13: 28-33.
21. rd ed. Paris, MSF/IUATLD, 2013.